🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Deguelin inhibits perineural invasion in esophageal squamous cell carcinoma via targeting BDNF/TrkB axis.

PMID: 41851958 · DOI: 10.1080/15384047.2026.2644788 · Cancer biology & therapy, 2026 · Qiying Wei, Liuyang Bai, Liangying Yan, Zhongyu Wang, Rongyao Jin, Bingjie Li, Wenbo Cao, Saijun Mo
📄 Abstract

Perineural invasion (PNI) represents a uniquely distinctive pathway for tumor metastasis, but its underlying molecular mechanisms and therapy remain unclear. Bioinformatics analysis and transcriptomic sequencing were first employed to investigate the involvement of the BDNF/TrkB axis in the ESCC PNI, which was validated with ESCC cells co-cultured with a dorsal root ganglia system (ESCC/DRG model), a mouse PNI model, and ESCC tissues, mainly using microscopic imaging, IVIS Spectrum The BDNF/TrkB axis is closely associated with the PNI in ESCC. This pathway plays a pivotal role in driving PNI progression via Akt signaling. Deguelin was identified as an effective inhibitor of PNI in ESCC. Mechanistically, BDNF was revealed to be a key binding target of Deguelin, which disrupts PNI development by modulating the BDNF/TrkB/Akt axis. Notably, overexpression of BDNF can counteract Deguelin's inhibitory effects on ESCC growth and PNI progression. The BDNF/TrkB axis promotes the progression of ESCC PNI, and Deguelin inhibits ESCC PNI by targeting this axis, enhancing the understanding of PNI's molecular mechanisms and offering new therapeutic options.

Confidence: 0.4 · 11 полей извлечено
Идентификация (6 полей)
Target
BDNF
0.95
Alt. target
0.00
Protein family
neurotrophin
0.90
Functional class
growth factor
0.90
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
ESCC tissues
0.90
In vitro
ESCC cells co-cultured with dorsal root ganglia system (ESCC/DRG model)
0.90
In vivo
mouse PNI model
0.90
In silico
Bioinformatics analysis and transcriptomic sequencing
0.90
Genetic association
0.00
Ex vivo
0.00
Animal model
mouse PNI model
0.90
Diet/model
0.00
Клиника (11 полей)
Drug
Deguelin
0.95
Indication
Esophageal squamous cell carcinoma
0.90
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
False
0.80